High Billing by Labs Continues to Be Trigger for Audits
As we move further into 2023, COVID-19, add-on, and genetic tests will likely remain targets for federal regulators.
As we move further into 2023, COVID-19, add-on, and genetic tests will likely remain targets for federal regulators.
Recent fraud case involving phlebotomy company shows why labs need to pay special attention to Medicare specimen collection and travel allowance rules.
A look at the US end-of-emergency game plan and how it will impact lab compliance.
FDA will still be able to issue EUAs for COVID-19 tests after May 11.
Your current COVID-19 testing arrangements may no longer be compliant on May 11.